69 results about "Influenza prevention" patented technology

Provided herein are immunogenic compositions comprising a chimeric influenza A virus HA and a CpG oligonucleotide adjuvant. Also provided herein are immunogenic compositions comprising an inactivated influenza A virus described herein or inactivated split influenza A virus described herein and a CpG oligonucleotide adjuvant described herein, wherein the inactivated influenza A virus or inactivated split influenza A virus comprises a chimeric hemagglutinin described herein. The immunogenic compositions may be used in a sequential immunization regimen. Also provided herein are methods of immunizing a subject against influenza virus disease (e.g., influenza virus disease caused by influenza A virus, such as, e.g., group 2 influenza A virus) using an immunogenic composition described herein. Further, provided herein are methods of preventing influenza virus disease (e.g., influenza virus disease caused by influenza A virus, such as, e.g., group 2 influenza A virus) in a subject using an immunogenic composition described herein.

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is comprised between 1.5:1 and 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and / or Influenza B.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

This application belongs to the field of pharmaceutical technology. More specifically, it relates to the use of sodium metatungstate in the preparation of drugs for treating or preventing influenza virus infection. Experiments have shown that sodium metatungstate has a broad-spectrum anti-influenza virus effect and can effectively inhibit influenza virus strains of different serotypes such as H1N1 and H3N2 on cell models. In addition, it also has an inhibitory effect on oseltamivir-resistant virus strains. The study on the anti-influenza virus mechanism of sodium metatungstate found that sodium metatungstate does not directly inactivate influenza virus; although it causes agglutination of the virus during the virus adsorption process, it does not affect the occurrence of adsorption, nor does it affect the process of the virus being endocytosed into the cytoplasm. However, sodium metatungstate will block the nuclear entry of influenza virus vRNP, thereby inhibiting virus replication.

The present invention belongs to the field of traditional Chinese medicine technology, and specifically relates to a traditional Chinese medicine composition for preventing influenza, its preparation method, and application. The composition comprises the following raw materials in parts by weight: 6-30g of raw coix seed, 5-30g of kapok flower, 3-20g of patchouli, 3-15g of perilla leaf, 3-15g of siler, 3-15g of forsythia, 3-20g of astragalus, and 5-20g of ginger. The traditional Chinese medicine composition of the present application uses authentic Lingnan medicinal materials, is simple, convenient, inexpensive, and effective, and can treat both cold and warm effects, dispel pathogenic factors without damaging the body's health, strengthen the body's health without restraining pathogenic factors, and eliminate dampness without damaging yin. It dispels pathogenic factors and strengthens the body's health simultaneously, has a good effect on preventing influenza, can enhance the body's immunity, and has a good preventive and health-care effect.

The invention discloses 3, 3', 4, 4', 5, 5' -hexahydroxy-trans-stilbene or a pharmaceutically acceptable ester thereof, for use in the treatment and prevention of infections with influenza virus in a human subject, especially for inhibiting human influenza virus.

The invention discloses an application of triptolide ketone in preparation of a preparation which is independently used or used in combination with other preparations to prevent and treat influenza, slow down influenza or inhibit influenza virus proliferation. The triptonide and the composition containing the triptonide are good in safety, can well inhibit influenza virus proliferation, and have application prospects for treating influenza.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.

The application discloses use of vocolotab in preparation of a preparation for preventing, treating, alleviating or inhibiting influenza virus proliferation, alone or in combination with other preparations. Vocolotab and the composition containing vocolotab are safe, can well inhibit influenza virus proliferation, and have application prospect in treating influenza.

The invention discloses a mixed vaccine for preventing influenza and novel coronavirus infections. As a mixed vaccine for vaccination against influenza and novel coronavirus, a whole virus inactivated vaccine obtained by inactivating virus particles of influenza virus and novel coronavirus is used, whereby a neutralizing antibody against each virus is induced without affecting the effect of each vaccine. And a defense effect is obtained for attack of each virus. In addition, the mixed vaccine based on the combination shows a good neutralizing antibody induction and virus attack defense effect even if an adjuvant is not added.

The present invention relates, in particular, to an immunogenic composition for use in the treatment or prevention of infection by influenza virus. The immunogenic composition comprises (a) a first nucleic acid encoding the hemagglutinin (HA) antigen of a strain of a first subtype of influenza A virus, (b) a second nucleic acid encoding the HA antigen of a strain of a second subtype of influenza A virus, (c) a third nucleic acid encoding the HA antigen of a first strain of influenza B virus, and (d) a fourth nucleic acid, optionally included, encoding the HA antigen of a second strain of influenza B virus, wherein the immune response is induced against the aforementioned strains of the first and second subtypes of influenza A virus, the aforementioned first strain and optionally included second strain of influenza B virus, and the HA antigen of at least one further HA antigen subtype of influenza A virus (different from any of the HA antigen subtypes of influenza A virus encoded by the nucleic acids present in the composition). [No selection diagram available]

The invention discloses penicillium, a compound separated from a fermentation product of the penicillium and application of the penicillium. The compound provided by the invention is shown as a formula (V). The invention also protects the application of any one of the compounds or the pharmaceutically acceptable salt thereof: (a1) the application in preparation of an influenza virus inhibitor; (a2) application in preparation of drugs for treating and / or preventing influenza virus infection. The invention also protects a strain of penicillium, and the preservation registration number is CGMCC (China General Microbiological Culture Collection Center) No.40910. The invention also protects a preparation method of the compound, and the preparation method comprises the following steps: carrying out fermentation culture on the penicillium to obtain the compound. The invention has important application value in prevention and control of influenza virus, and can be used in the field of medicines, clinical treatment and public health.

Synthetic nutritional composition comprising a phospholipid-enriched milk fraction and a milk serum protein concentrate (SPC) for use in the prevention of an influenza virus and / or the prevention of further development of a viral infection with influenza virus.

This invention belongs to the field of biomedical technology, specifically disclosing a scorpion-derived polypeptide for combating influenza virus and its applications. The scorpion-derived polypeptide has the amino acid sequence shown in SEQ ID NO:1, or is a functional variant obtained by substitution, deletion, and / or addition of one or more amino acids from the same sequence, retaining its anti-influenza virus activity. The scorpion-derived polypeptide provided by this invention can significantly inhibit the proliferation of influenza A virus and substantially reduce the expression levels of viral RNA and protein within a non-cytotoxic concentration range. It also effectively reduces viral load and inflammatory factor levels in mice infected with influenza A virus, exhibiting excellent anti-influenza A virus activity and being less likely to induce viral resistance. This invention provides a novel, highly efficient, and low-toxicity bioactive molecule for influenza prevention and control, which can be applied to the development of anti-influenza drugs.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention discloses an application of vocerotropine in preparation of a preparation which is independently used or used in combination with other preparations to prevent and treat influenza, slow down influenza or inhibit influenza virus proliferation. The vocerotropine and the composition containing the vocerotropine are good in safety, can well inhibit influenza virus proliferation, and have application prospects for treating influenza.

The invention discloses application of verbascoside in preparation of a product for preventing and treating influenza virus infection, and relates to the technical field of biological medicines. Through molecular docking screening, cytotoxicity experiments and antiviral activity verification, the application value of verbascoside in prevention and treatment of influenza virus infection is defined, and the technical effect is remarkable. In the aspect of safety, the verbascoside has no obvious influence on the survival rate of MDCK cells at the concentration of 200 mu M, the concentration of the verbascoside is far higher than the clinical potential medication concentration, and the verbascoside has no obvious cytotoxicity and good biocompatibility. In the aspect of antiviral activity, verbascoside shows an efficient inhibition effect on influenza viruses (WSN strains and FM1 strains), the IC50 value is as low as 28.3 mu M, and the inhibition effect is superior to that of part of natural components. In an application scene, verbascoside can be prepared into various drug dosage forms and can also be used as an active ingredient of a disinfectant, and a novel safe, efficient and multifunctional flu prevention and control scheme is provided for the field of biological medicine.

The utility model provides an electronic atomizer with an influenza prevention function, which relates to the technical field of electronic atomizers and comprises a stainless steel shell, liquid storage cotton and a lithium battery core are respectively arranged inside the stainless steel shell and close to two ends, liquid guide cotton is arranged between the liquid storage cotton and the lithium battery core, and one end of the liquid guide cotton is tightly attached to one end of the liquid storage cotton. The liquid storage cotton draws flu prevention atomized liquid into the liquid storage cup through capillary force and is in a saturated adsorption state, at the moment, when a user actively draws an air outlet of the liquid storage cup, certain pressure is generated in an air channel, an air sensor is triggered to work, current is conducted, and after a heating body on the atomization component is powered on, the flu prevention atomized liquid flows into the liquid storage cup. The temperature rises and reaches the boiling point of the flu prevention atomized liquid, the flu prevention atomized liquid evaporates to generate steam, under the suction effect, the steam is brought into the airway by airflow and condensed to form aerosol in the movement process of the airway, the flu prevention effect can be achieved for a patient, and therefore the effect of improving the performance of the atomizer can be achieved.

To provide a composition for treating and / or preventing influenza, food and drink, and feed, which are excellent in safety as well as preventive effect and treatment effect.SOLUTION: The present disclosure provides a composition for treating and / or preventing influenza containing a retinoid compound as an active ingredient.SELECTED DRAWING: Figure 2

The present disclosure provides vaccine compositions comprising a plurality of different antigens. Also provided are nucleic acid vaccine compositions comprising one or more nucleic acids encoding a plurality of different antigens. The plurality of different antigens include a combination of influenza antigens. The vaccine compositions may be formulated as mRNA / LNP, recombinant proteins, virus-like particles (VLPs), or DNA for delivery. Methods of preventing influenza infection and methods of inducing an immune response are also disclosed.

Provided herein are universal prophylactic compositions for preventing infection with influenza viruses by directing the immune response to highly conserved regions of the virus. Also provided are universal therapeutic compositions for treating influenza infection by targeting the highly conserved regions. Methods for using the prophylactic and therapeutic compositions are also provided.

The present invention relates inter alia to an immunogenic composition for use in the treatment or prevention of influenza virus infection, wherein the immunogenic composition comprises: (a) a first nucleic acid encoding a hemagglutinin (HA) antigen of a first subtype strain of influenza A virus; (b) a second nucleic acid encoding an HA antigen of a second subtype strain of influenza A virus; (c) a third nucleic acid encoding the HA antigen of the first strain of influenza B virus; and (d) optionally, a fourth nucleic acid encoding an HA antigen of a second strain of influenza B virus, wherein the first subtype and the second subtype strains of the influenza A virus are used for detecting the first subtype and the second subtype strains; the HA antigens of the first and optional second strains of the influenza B virus and of at least one other HA antigen subtype of the influenza A virus different from any HA antigen subtype of the influenza A virus encoded by the nucleic acid present in the composition elicit an immune response.

The present invention is in the field of treating and / or preventing viral infections. In particular, the present invention relates to immunogenic or pharmaceutical compositions comprising self-replicating RNA molecules that encode influenza virus antigens for treating and / or preventing influenza infections.

The present disclosure provides methods for inhibiting entry of a virus into a host cell using picolinic acid or a salt or derivative thereof. The present disclosure also provides methods for treating or preventing a viral infection in a subject by administering picolinic acid or a salt or derivative thereof. In particular, the methods of the present disclosure are effective for enveloped viruses and syncytium-forming viruses. In some embodiments, the present disclosure provides methods of treating or preventing a SARS CoV-2, Influenza A virus, human parainfluenza virus, herpes simplex virus, Japanese encephalitis virus, Zika virus, or a flavivirus infection.

The present disclosure relates to compositions comprising RNA molecules encoding influenza-derived antigens, where the RNA may be formulated in lipid nanoparticles (LNPs), and the compositions further comprise a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or an RNA molecule encoding an antigen derived from RSV, where the RSV RNA may be formulated in LNPs. The present disclosure further relates to the use of RNA molecules, RNA-LNPs, and compositions for the prevention of influenza and RSV infection-induced illnesses.

The invention discloses an anti-influenza A virus micropeptide uYIPF2 coded by an upstream open reading frame of a YIPF2 gene and application thereof, and relates to the technical field of biological medicines. The micropeptide uYIPF2 is coded by an upstream open reading frame (uORF) of a YIPF2 gene, contains 87 amino acids, and has a specific sequence as shown in SEQ ID No.1. A hemagglutination test and a plaque test prove that the micropeptide uYIPF2 can significantly reduce the HA titer and the virus load of the influenza A virus, and can significantly inhibit the replication of the influenza A virus. The invention reveals that the uYIPF2 micro-peptide has an anti-influenza A virus biological function for the first time, and provides application of the uYIPF2 micro-peptide in preparation of drugs for preventing and treating influenza A virus infection. The invention provides a brand-new drug target and a treatment strategy for the field of flu prevention and treatment.

The application discloses use of mizoribine in preparation of a preparation for preventing, treating, alleviating or inhibiting influenza virus proliferation, alone or in combination with other preparations. The mizoribine and the composition containing the mizoribine are safe, can well inhibit influenza virus proliferation, and have application prospect in treating influenza.

The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.